



## REASONS TO CONSIDER

**High Growth Potential**

Manufacturing genomic medicines is cumbersome, but new techniques using donated cells are more scalable and could slash production costs by 95%, potentially facilitating broader adoption.<sup>(1)</sup>

**Structural Tailwinds**

Recent regulatory approvals have helped genomic medicines gain momentum. Sales of genomic medicines are forecast to increase at a 39% compound annual growth rate from 2024-2030.<sup>(2)</sup>

**Targeted Exposure**

GNOM provides global exposure to emerging areas within the Health Care sector, at the intersection of science and technology.

## KEY INFORMATION

Inception Date	04/05/2019
Underlying Index	Solactive Genomics Index
Number of Holdings	40
Assets Under Management	\$51.25 mil
Total Expense Ratio	0.50%
Distribution Frequency	Semi-Annually

## TRADING DETAILS

Ticker	GNOM
CUSIP	37954Y434
Exchange	NASDAQ
Bloomberg IOPV Ticker	GNOMIV
Index Ticker	SOLGNOM

## PERFORMANCE (%)


	1M	YTD	1Y	3Y	5Y	Since Inception
NAV	-13.00%	-17.22%	-29.31%	-18.84%	-8.64%	-10.16%
Market Price	-13.87%	-18.13%	-30.14%	-19.13%	-8.81%	-10.03%
Index	-12.98%	-17.13%	-28.88%	-18.39%	-8.17%	-9.68%

TOP 10 HOLDINGS (%) *Holdings Subject to Change*

Natera Inc	6.36%	Agilent Technologies Inc	4.69%
Biomarin Pharmac	5.38%	Bio-technie Corp	4.51%
Qiagen N.v.	5.16%	Biontech Se-adr	4.37%
Veracyte Inc	5.08%	Genscript Biotech Corp	4.21%
Alnylam Pharmace	5.07%	Legend Biotech Corp-adr	4.12%


The performance data quoted represents past performance and does not guarantee future results. Investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost. Current performance may be higher or lower than the performance quoted. High short-term performance, when observed, is unusual and investors should not expect such performance to be repeated. Returns for periods greater than one year are annualized. For performance data current to the most recent month end, please call 1-888-493-8631, or visit [www.globalxetfs.com](http://www.globalxetfs.com).

## INDUSTRY BREAKDOWN (%)



Pharmaceuticals, Biotechnology & Life Sciences	98.81%
Health Care Equipment & Services	0.90%
Pharmaceuticals, Biotechnology	0.29%

## COUNTRY BREAKDOWN (%)



United States	80.76%
Netherlands	6.23%
China	4.52%
Germany	4.51%
Switzerland	3.99%

All Sector, Industry and Geographic breakdowns, where provided, are based on equity positions held by the ETF and exclude cash, currencies, and other holdings.



## DEFINITIONS

### Solactive Genomics Index

The Solactive Genomics Index tracks the companies that generate revenues from Genomics related business. Genomics business operations include the following: (i) gene editing, (ii) genomic sequencing, (iii) development and testing of genetic medicine/therapies, (iv) computational genomics and genetic diagnostics, and/or (v) biotechnology.

(1) International Society for Cell and Gene Therapy, Feb 2019

(2) Evaluate Pharma, n.d., Technology Overviews of: Cell Therapy, Gene Therapy, Gene-Modified Cell Therapy, and Genome Editing, all accessed 1 Nov 2024

Investing involves risk, including the possible loss of principal. The investable universe of companies in which GNOM may invest may be limited. The Fund invests in securities of companies engaged in Genomics, Healthcare and Biotechnology sectors. These sectors can be affected by government regulations, rapid product obsolescence, intense industry competition and loss or impairment of patents or intellectual property rights. International investments may involve risk of capital loss from unfavorable fluctuation in currency values, from differences in generally accepted accounting principles or from social, economic or political instability in other nations. GNOM is non-diversified. The information provided is not intended for trading purposes, and should not be considered investment advice.

**Carefully consider the Fund's investment objectives, risk factors, charges, and expenses before investing. This and additional information can be found in the Fund's full or summary prospectus, which may be obtained by calling 1.888.493.8631, or by visiting [globalxetfs.com](http://globalxetfs.com). Please read the prospectus carefully before investing.**

Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. Beginning October 15, 2020, market price returns are based on the official closing price of an ETF share or, if the official closing price isn't available, the midpoint between the national best bid and national best offer ("NBBO") as of the time the ETF calculates current NAV per share. Prior to October 15, 2020, market price returns were based on the midpoint between the Bid and Ask price. NAVs are calculated using prices as of 4:00 PM Eastern Time. The returns shown do not represent the returns you would receive if you traded shares at other times. Indices are unmanaged and do not include the effect of fees, expenses or sales charges. One cannot invest directly in an index.

Since the Fund's shares did not trade in the secondary market until several days after the Fund's inception, for the period from inception to the first day of secondary market trading in Shares, the NAV of the Fund is used to calculate market returns.

Global X Management Company LLC serves as an advisor to the Global X Funds. The Funds are distributed by SEI Investments Distribution Co. (SIDCO, 1 Freedom Valley Drive, Oaks, PA, 19456), which is not affiliated with Global X Management Company LLC or Mirae Asset Global Investments. Global X Funds are not sponsored, endorsed, issued, sold or promoted by Solactive AG, nor does Solactive AG make any representations regarding the advisability of investing in the Global X Funds. Neither SIDCO, Global X nor Mirae Asset Global Investments are affiliated with Solactive AG.